KaloBios Pharma (KBIO) Tops Q2 EPS by 22c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/6/2026

1. USO
2. SPY
3. MRVL
4. CHRW
5. APLD
6. AMD
7. HUBS
8. RXO
9. OPCH
10. BBIO

Go back to KaloBios Pharma (KBIO) Tops Q2 EPS by 22c

KaloBios Reports Second Quarter Financial Results and Provides Clinical Update

August 10, 2015 8:01 AM EDT

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), a monoclonal antibody company focused on oncology, today announced its financial results for the second quarter of 2015 and provided an update on its clinical development progress.

Second Quarter 2015 Financial Results

Net loss for the quarter ended June 30, 2015 was $6.0 million or $1.46 per common share, as compared to $9.8 million or $2.38 per common share for the same period in 2014. All per-share amounts have been adjusted to reflect the... More